Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that Chief Executive Officer Ilya Rachman, MD, PhD, and Chief Financial Officer Gabriel Morris will present […]
ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 A photo accompanying […]
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92 LOS ANGELES, Sept. 07, 2022 — Immix Biopharma, Inc. […]
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs IMX-110 is in clinical development for STS, a $3 billion […]
Immix Biopharma Announces Share Repurchase Program
LOS ANGELES, May 09, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company’s common stock. The Company may […]
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022
The IMMX Milestone Day Event is viewable at immixbio.com/Apr2022MilestoneDay Management discussed financial position, milestones, and new opportunities presented by current market volatility ImmixBio plans to commence 2 clinical trials in 2022 LOS ANGELES, April 05, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting […]
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility With $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29ada955-df7a-4722-968a-3a3e0fd0d34d LOS ANGELES, March 07, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) […]
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells ImmixBio anticipates filing an IND for IMX-120 in 2023 The inflammatory bowel disease market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019 A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4733027e-ec5e-4598-9b6e-d5a9c4031c56 LOS ANGELES, […]
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
LOS ANGELES, Feb. 01, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET. ImmixBio […]
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data
Manufactured IMX-110 to be utilized in both clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors An image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d. LOS ANGELES, Jan. 31, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, […]